6Purrello F, Rabuazza AM. Metabolic factors that affect betacell function and survival. Diabet Nutr Metab, 2000, 13: 84-91.
7Sivitz WI. Lipotoxieity and glueotoxieity in type 2 diabetes. Effects on development and progression. Postgrad Med, 2001,109: 55-59,63-64.
8Lenhard M J, Reeves GD. Continous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy. Arch Intern Med,2001,161: 2293-2300.
9Dupuy O, Mayaudon H, Palou M, et al. Optimized transient insulin infusion in uneontrolled type 2 Diabetes : Evaluation of a pragmatie attitude. Diabet Med, 2000,26 : 371-375.
10Valensi P, Moura I, Magoarou M,et al. Short-term effects of continuous subcutaneous insulin infusion treatment on insulin secretion in non-insulin-dependent overweight patients with poor glycaemic control despite maximal oral anti-diabetic treatment. Diabet Metab,1997,23: 51-57.
3Huen KF,Low LC,Wong GW,et al. Epidemi-ology of diabetes mellitus in children in Hong Kong:the Hong Kongchildhood diabetes regis- ter[ J]. J Pediatr Endocrinol Metab,2000,13 (3) :297 -302.
4HmIsan K, Loar R,Anderson BJ,et al. Et le role of C status, depression, quality of life, and glyeemie control in type 1 diabetes mellitus [ J ]. J Pedi- atr,2006,149(4) :526 -531.
